OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
002919$26.8356

MINGCHEN HEALTH Co Ltd

Personal ProductsVerified

The company's capital structure is characterized by a low debt-to-equity ratio of 0.14, indicating a conservative leverage profile. However, its liquidity position is assessed as medium, with negative net cash after subtracting total debt. The price-to-book ratio of 8.86 and price-to-tangible-book ratio of 8.86 suggest that the market is valuing the company's intangible assets at a premium relative to its tangible book value. The company's free cash flow is negative at -49.37 million CNY, driven by capital expenditures of -86.51 million CNY, which may signal ongoing investment in growth or operational expansion. Profitability metrics show a return on equity (ROE) of 3.51% and a return on assets (ROA) of 2.2%, both of which are below the typical thresholds for high-performing companies in the personal care products industry. The gross profit margin is 53.73% (813.73 million CNY on 1.51 billion CNY revenue), but the operating margin is only 3.61% (54.71 million CNY), indicating significant operating expenses relative to gross profit. The net income margin is 1.87% (28.31 million CNY), which is relatively low for a company in the consumer non-cyclical sector. Geographically, the company's revenue is concentrated in China, with no disclosed international operations. The company operates in a single business segment, which may increase its exposure to regional economic and regulatory risks. There is no information on revenue concentration by product line or customer, but the single-segment structure suggests a lack of diversification. The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future guidance. The price-to-earnings ratio of 252.61 and enterprise value-to-revenue ratio of 4.8 suggest that the market is pricing in low near-term earnings growth expectations. The company's capital expenditures of -86.51 million CNY may indicate investment in future capacity or product development, but the negative free cash flow suggests that these investments are not yet generating positive cash returns. The risk assessment highlights a medium liquidity risk, with negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. The company's capital structure is relatively conservative, with long-term debt of 111.83 million CNY and total liabilities of 477.53 million CNY, but the negative net cash position raises concerns about short-term liquidity. Recent events and filings do not provide specific details on material developments, but the company's financial snapshot indicates a need for continued monitoring of its liquidity position and capital expenditures. The company's high price-to-earnings ratio and low profitability metrics suggest that investors are placing a premium on future growth potential rather than current earnings performance.

30-day price · 002919(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyMINGCHEN HEALTH Co Ltd
Ticker002919.SZ
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Products
AI analysis

Business. MINGCHEN HEALTH Co Ltd is a personal products company that develops, produces, and sells health and beauty products, primarily in the Chinese market.

Classification. The company is classified under the Consumer Non-Cyclicals economic sector, Personal & Household Products & Services business sector, and Personal Products industry with a confidence level of 0.92.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.14, indicating a conservative leverage profile. However, its liquidity position is assessed as medium, with negative net cash after subtracting total debt. The price-to-book ratio of 8.86 and price-to-tangible-book ratio of 8.86 suggest that the market is valuing the company's intangible assets at a premium relative to its tangible book value. The company's free cash flow is negative at -49.37 million CNY, driven by capital expenditures of -86.51 million CNY, which may signal ongoing investment in growth or operational expansion. Profitability metrics show a return on equity (ROE) of 3.51% and a return on assets (ROA) of 2.2%, both of which are below the typical thresholds for high-performing companies in the personal care products industry. The gross profit margin is 53.73% (813.73 million CNY on 1.51 billion CNY revenue), but the operating margin is only 3.61% (54.71 million CNY), indicating significant operating expenses relative to gross profit. The net income margin is 1.87% (28.31 million CNY), which is relatively low for a company in the consumer non-cyclical sector. Geographically, the company's revenue is concentrated in China, with no disclosed international operations. The company operates in a single business segment, which may increase its exposure to regional economic and regulatory risks. There is no information on revenue concentration by product line or customer, but the single-segment structure suggests a lack of diversification. The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future guidance. The price-to-earnings ratio of 252.61 and enterprise value-to-revenue ratio of 4.8 suggest that the market is pricing in low near-term earnings growth expectations. The company's capital expenditures of -86.51 million CNY may indicate investment in future capacity or product development, but the negative free cash flow suggests that these investments are not yet generating positive cash returns. The risk assessment highlights a medium liquidity risk, with negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. The company's capital structure is relatively conservative, with long-term debt of 111.83 million CNY and total liabilities of 477.53 million CNY, but the negative net cash position raises concerns about short-term liquidity. Recent events and filings do not provide specific details on material developments, but the company's financial snapshot indicates a need for continued monitoring of its liquidity position and capital expenditures. The company's high price-to-earnings ratio and low profitability metrics suggest that investors are placing a premium on future growth potential rather than current earnings performance.
Key takeaways
  • The company has a conservative capital structure with a low debt-to-equity ratio of 0.14.
  • Profitability metrics are weak, with ROE of 3.51% and ROA of 2.2%.
  • The company's liquidity position is medium, with negative net cash after subtracting total debt.
  • The company operates in a single business segment and geographic market, increasing its exposure to regional risks.
  • The high price-to-earnings ratio of 252.61 suggests that the market is pricing in low near-term earnings growth expectations.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.51B
Gross profit$813.7M
Operating income$54.7M
Net income$28.3M
R&D
SG&A
D&A
SBC
Operating cash flow$87.7M
CapEx-$86.5M
Free cash flow-$49.4M
Total assets$1.28B
Total liabilities$477.5M
Total equity$807.3M
Cash & equivalents
Long-term debt$111.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$1.51B$54.7M$28.3M-$49.4M
FY-1$1.38B$31.3M$46.7M$11.5M
FY-2$1.64B$57.9M$70.4M$232.3M
FY-3$945.4M-$5.5M$25.3M-$112.2M
FY-4$744.1M$126.6M$133.5M$109.2M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$1.28B$807.3M
FY-1$1.10B$823.3M
FY-2$1.27B$809.9M
FY-3$1.24B$739.2M
FY-4$970.3M$757.8M
PeriodOCFCapExFCFSBC
FY0$87.7M-$86.5M-$49.4M
FY-1$165.3M-$48.6M$11.5M
FY-2$69.3M-$12.7M$232.3M
FY-3$73.3M-$150.5M-$112.2M
FY-4$79.9M-$15.5M$109.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$417.5M$4.8M$9.2M
FQ-1$435.6M$16.2M-$14.2M
FQ-2$367.2M$1.4M$1.5M
FQ-3$350.2M$22.4M$28.3M
FQ-4$361.4M$14.8M$12.7M
FQ-5$395.5M-$78.1M-$50.1M
FQ-6$320.0M$42.9M$36.4M
FQ-7$302.9M$18.3M$15.6M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$1.28B$816.5M$180.7M
FQ-1$1.28B$807.3M
FQ-2$1.17B$821.6M$126.4M
FQ-3$1.15B$831.1M
FQ-4$1.12B$836.1M$113.6M
FQ-5$1.10B$823.3M
FQ-6$1.20B$873.4M$133.9M
FQ-7$1.21B$837.0M
PeriodOCFCapExFCFSBC
FQ0$14.0M-$11.9M
FQ-1$87.7M-$86.5M
FQ-2$39.9M-$61.8M
FQ-3-$827.8k-$39.8M
FQ-4-$52.8M-$10.4M
FQ-5$165.3M-$48.6M
FQ-6$56.7M-$5.6M
FQ-7$32.5M-$2.2M
Valuation
Market price$26.83
Market cap$7.15B
Enterprise value$7.26B
P/E252.6
Reported non-GAAP P/E
EV/Revenue4.8
EV/Op income132.8
EV/OCF82.9
P/B8.9
P/Tangible book8.9
Tangible book$807.3M
Net cash-$111.8M
Current ratio1.7
Debt/Equity0.1
ROA2.2%
ROE3.5%
Cash conversion3.1%
CapEx/Revenue-5.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Personal Products · cohort 225 companies
Metric002919Activity
Op margin3.6%16.2% medp25 16.2% · p75 16.2%bottom quartile
Net margin1.9%10.5% medp25 10.5% · p75 10.5%bottom quartile
Gross margin53.7%60.1% medp25 60.1% · p75 60.1%bottom quartile
R&D / revenue1.8% medp25 1.8% · p75 1.8%
CapEx / revenue-5.7%-2.3% medp25 -4.4% · p75 -1.1%bottom quartile
Debt / equity14.0%12724.1% medp25 12724.1% · p75 12724.1%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-18 00:36 UTCJob: 8cd90fa6